Anna Lembke, MD, discusses how patients who use drugs are affected by the convergence of 2 public health emergencies – increasing overdose rates, and the COVID-19 pandemic – and addresses controversial solutions proposed by other investigators.
The FDA has issued a warning letter to AcelRx Pharmaceuticals, the manufacturer of Dsuvia, for disseminating false and misleading promotional communications.
The purpose of this study was to examine 2017 US national and state variation in neonatal abstinence syndrome and maternal opioid-related diagnoses rates in 2017 and changes since 2010.
A pain management regimen that uses mostly over-the-counter medication reduces opioid exposure in trauma patients while achieving similar levels of pain control.
The authors propose evaluating which aspects of previous policy and practices for OUD should resume and which aspects of current policy and practice exemptions should continue.
